Giulio Superti-Furga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2667650/publications.pdf

Version: 2024-02-01

269 papers	39,836 citations	3149 92 h-index	2736 192 g-index
313 all docs	313 docs citations	313 times ranked	49889 citing authors

#	Article	IF	Citations
1	Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature, 2002, 415, 141-147.	13.7	4,509
2	Proteome survey reveals modularity of the yeast cell machinery. Nature, 2006, 440, 631-636.	13.7	2,347
3	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. New England Journal of Medicine, 2013, 369, 2379-2390.	13.9	1,698
4	The CRAPome: a contaminant repository for affinity purificationâ€“mass spectrometry data. Nature Methods, 2013, 10, 730-736.	9.0	1,353
5	A physical and functional map of the human TNF-Î±/NF-ÎºB signal transduction pathway. Nature Cell Biology, 2004, 6, 97-105.	4.6	970
6	An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nature Immunology, 2009, 10, 266-272.	7.0	935
7	Gene essentiality and synthetic lethality in haploid human cells. Science, 2015, 350, 1092-1096.	6.0	773
8	Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase. Cell, 2003, 112, 859-871.	13.5	762
9	Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity. Cell, 2010, 141, 668-681.	13.5	717
10	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	3.9	698
11	Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chemical Biology, 2015, 10, 1604-1609.	1.6	629
12	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063.	0.6	600
13	SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature, 2015, 519, 477-481.	13.7	561
14	ELM server: a new resource for investigating short functional sites in modular eukaryotic proteins. Nucleic Acids Research, 2003, 31, 3625-3630.	6.5	555
15	Target profiling of small molecules by chemical proteomics. Nature Chemical Biology, 2009, 5, 616-624.	3.9	505
16	Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature, 2011, 478, 76-81.	13.7	469
17	A Call for Systematic Research on Solute Carriers. Cell, 2015, 162, 478-487.	13.5	457
18	Regulation of the c-Abl and Bcrâ€“Abl tyrosine kinases. Nature Reviews Molecular Cell Biology, 2004, 5, 33-44.	16.1	429

#	Article	IF	Citations
19	Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter. Cell, 1987, 50, 347-359.	13.5	428
20	IFIT1 is an antiviral protein that recognizes 5â€²-triphosphate RNA. Nature Immunology, 2011, 12, 624-630.	7.0	422
21	A Myristoyl/Phosphotyrosine Switch Regulates c-Abl. Cell, 2003, 112, 845-857.	13.5	404
22	Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature, 1999, 401, 926-929.	13.7	394
23	Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO Journal, 1999, 18, 2137-2148.	3.5	393
24	Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO Journal, 1997, 16, 706-716.	3.5	373
25	Structure-Based Assembly of Protein Complexes in Yeast. Science, 2004, 303, 2026-2029.	6.0	367
26	Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation. Cell, 2001, 105, 115-126.	13.5	366
27	An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nature Methods, 2006, 3, 1013-1019.	9.0	366
28	Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 2014, 508, 222-227.	13.7	336
29	Artemisinins Target GABAA Receptor Signaling and Impair Î± Cell Identity. Cell, 2017, 168, 86-100.e15.	13.5	330
30	The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO Journal, 2008, 27, 2135-2146.	3.5	276
31	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13283-13288.	3.3	274
32	The minimum information required for reporting a molecular interaction experiment (MIMIx). Nature Biotechnology, 2007, 25, 894-898.	9.4	274
33	Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nature Medicine, 2014, 20, 47-53.	15.2	256
34	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 2009, 23, 477-485.	3.3	254
35	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chemical Biology, 2010, 6, 291-299.	3.9	254
36	Viral immune modulators perturb the human molecular network by common and unique strategies. Nature, 2012, 487, 486-490.	13.7	249

#	Article	IF	Citations
37	Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Human Molecular Genetics, 2000, 9, 2223-2229.	1.4	247
38	Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src.. EMBO Journal, 1993, 12, 2625-2634.	3.5	244
39	The 2.35 Ã¥ crystal structure of the inactivated form of chicken src: a dynamic molecule with multiple regulatory interactions. Journal of Molecular Biology, 1997, 274, 757-775.	2.0	243
40	RhoB and Actin Polymerization Coordinate Src Activation with Endosome-Mediated Delivery to the Membrane. Developmental Cell, 2004, 7, 855-869.	3.1	235
41	Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leukemia and Lymphoma, 2008, 49, 615-619.	0.6	233
42	Pharmacological targeting of the Wdr5-MLL interaction in C/EBPÎ± N-terminal leukemia. Nature Chemical Biology, 2015, 11, 571-578.	3.9	227
43	Autoinhibition of c-Abl. Cell, 2002, 108, 247-259.	13.5	226
44	Mass spectrometryâ€“based functional proteomics: from molecular machines to protein networks. Nature Methods, 2007, 4, 807-815.	9.0	223
45	NSs Protein of Rift Valley Fever Virus Induces the Specific Degradation of the Double-Stranded RNA-Dependent Protein Kinase. Journal of Virology, 2009, 83, 4365-4375.	1.5	216
46	c-Src-Mediated Phosphorylation of hnRNP K Drives Translational Activation of Specifically Silenced mRNAs. Molecular and Cellular Biology, 2002, 22, 4535-4543.	1.1	210
47	An intramolecular SH3-domain interaction regulates c-Abl activity. Nature Genetics, 1998, 18, 280-282.	9.4	206
48	The Fission Yeast pmk1⁺ Gene Encodes a Novel Mitogen-Activated Protein Kinase Homolog Which Regulates Cell Integrity and Functions Coordinately with the Protein Kinase C Pathway. Molecular and Cellular Biology, 1996, 16, 6752-6764.	1.1	201
49	Structure-function relationships in Src family and related protein tyrosine kinases. BioEssays, 1995, 17, 321-330.	1.2	195
50	Structural basis for viral 5â€²-PPP-RNA recognition by human IFIT proteins. Nature, 2013, 494, 60-64.	13.7	193
51	Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase. Molecular Cell, 2006, 21, 787-798.	4.5	192
52	Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nature Methods, 2013, 10, 307-314.	9.0	192
53	Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation. Cell, 2008, 134, 793-803.	13.5	190
54	Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nature Methods, 2015, 12, 1055-1057.	9.0	183

#	Article	IF	Citations
55	CD14 is a coreceptor of Toll-like receptors 7 and 9. Journal of Experimental Medicine, 2010, 207, 2689-2701.	4.2	181
56	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	3.6	181
57	A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses. Cell, 2015, 162, 170-183.	13.5	181
58	Rediscovering the sweet spot in drug discovery. Drug Discovery Today, 2003, 8, 1067-1077.	3.2	179
59	Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO Journal, 2006, 25, 1895-1905.	3.5	179
60	A guide to plasma membrane solute carrier proteins. FEBS Journal, 2021, 288, 2784-2835.	2.2	168
61	BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature Chemical Biology, 2012, 8, 285-293.	3.9	158
62	The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nature Chemical Biology, 2014, 10, 768-773.	3.9	157
63	A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death and Disease, 2015, 6, e1767-e1767.	2.7	157
64	Human Proteinpedia enables sharing of human protein data. Nature Biotechnology, 2008, 26, 164-167.	9.4	155
65	Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions.. EMBO Journal, 1995, 14, 963-975.	3.5	149
66	Charting the molecular network of the drug target Bcr-Abl. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7414-7419.	3.3	146
67	LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 2018, 362, 1171-1177.	6.0	142
68	The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO Journal, 1997, 16, 7261-7271.	3.5	138
69	A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nature Structural and Molecular Biology, 2010, 17, 519-527.	3.6	138
70	The â^'117 mutation in Greek HPFH affects the binding of three nuclear factors to the CCAAT region of the gamma-globin gene.. EMBO Journal, 1988, 7, 3099-3107.	3.5	133
71	Transgenic Mouse Proteomics Identifies New 14-3-3-associated Proteins Involved in Cytoskeletal Rearrangements and Cell Signaling. Molecular and Cellular Proteomics, 2006, 5, 2211-2227.	2.5	130
72	Interactome of Two Diverse RNA Granules Links mRNA Localization to Translational Repression in Neurons. Cell Reports, 2013, 5, 1749-1762.	2.9	130

#	Article	IF	Citations
73	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	2.2	130
74	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. Chemical Science, 2015, 6, 2449-2456.	3.7	127
75	Protein complexes and proteome organization from yeast to man. Current Opinion in Chemical Biology, 2003, 7, 21-27.	2.8	125
76	NANS-mediated synthesis of sialic acid is required for brain and skeletal development. Nature Genetics, 2016, 48, 777-784.	9.4	125
77	Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis. Cell, 2011, 147, 306-319.	13.5	122
78	SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutiÃ¨res syndrome-associated mutations. Human Mutation, 2012, 33, 1116-1122.	1.1	121
79	Internalization of Pseudomonas aeruginosa Strain PAO1 into Epithelial Cells Is Promoted by Interaction of a T6SS Effector with the Microtubule Network. MBio, 2015, 6, e00712.	1.8	121
80	General Statistical Modeling of Data from Protein Relative Expression Isobaric Tags. Journal of Proteome Research, 2011, 10, 2758-2766.	1.8	120
81	JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nature Genetics, 2014, 46, 1021-1027.	9.4	119
82	TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7â€“9. Nature, 2020, 581, 316-322.	13.7	117
83	Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nature Communications, 2014, 5, 5360.	5.8	116
84	FAM111A Mutations Result in Hypoparathyroidism and Impaired Skeletal Development. American Journal of Human Genetics, 2013, 92, 990-995.	2.6	114
85	Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nature Immunology, 2016, 17, 1361-1372.	7.0	114
86	Functional Dissection of the TBK1 Molecular Network. PLoS ONE, 2011, 6, e23971.	1.1	110
87	Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia, 2017, 31, 2388-2397.	3.3	110
88	c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO Journal, 2002, 21, 514-524.	3.5	109
89	IFITs: Emerging Roles as Key Anti-Viral Proteins. Frontiers in Immunology, 2014, 5, 94.	2.2	105
90	Hormone-dependent transcriptional regulation and cellular transformation by Fos-steroid receptor fusion proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5114-5118.	3.3	97

#	Article	IF	Citations
91	Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control?. Oncogene, 1997, 14, 2485-2495.	2.6	96
92	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chemical Biology, 2012, 8, 905-912.	3.9	96
93	Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nature Structural Biology, 2000, 7, 281-286.	9.7	95
94	Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. Cellular Microbiology, 2014, 16, 834-848.	1.1	94
95	Immunosuppression and atypical infections in CML patients treated with dasatinib at 140â€ƒmg daily. European Journal of Clinical Investigation, 2009, 39, 1098-1109.	1.7	92
96	LAMTOR/Ragulator is a negative regulator of Arl8b- and BORC-dependent late endosomal positioning. Journal of Cell Biology, 2017, 216, 4199-4215.	2.3	91
97	A reversible gene trap collection empowers haploid genetics in human cells. Nature Methods, 2013, 10, 965-971.	9.0	90
98	A complex prediction: threeâ€dimensional model of the yeast exosome. EMBO Reports, 2002, 3, 628-635.	2.0	89
99	KPC1-Mediated Ubiquitination and Proteasomal Processing of NF-Î¤B1 p105 to p50 Restricts Tumor Growth. Cell, 2015, 161, 333-347.	13.5	89
100	A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nature Chemical Biology, 2020, 16, 469-478.	3.9	84
101	The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Structural Biology, 2009, 9, 7.	2.3	83
102	Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO Journal, 1993, 12, 2625-34.	3.5	83
103	A nuclear tyrosine phosphorylation circuit: c-Jun as an activator and substrate of c-Abl and JNK. EMBO Journal, 2000, 19, 273-281.	3.5	81
104	Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase. Oncogene, 2001, 20, 8075-8084.	2.6	80
105	Recent advances in combinatorial drug screening and synergy scoring. Current Opinion in Pharmacology, 2018, 42, 102-110.	1.7	80
106	Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQÂ®-labelled specimens. Journal of Proteomics, 2011, 74, 151-166.	1.2	79
107	The effects of dasatinib on IgE receptorâ€“dependent activation and histamine release in human basophils. Blood, 2008, 111, 3097-3107.	0.6	78
108	Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import. Nature Communications, 2020, 11, 6145.	5.8	78

#	Article	IF	Citations
109	Plk1-Dependent Phosphorylation of Optineurin Provides a Negative Feedback Mechanism for Mitotic Progression. Molecular Cell, 2012, 45, 553-566.	4.5	77
110	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	7.7	77
111	The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity. Cell Reports, 2015, 11, 1919-1928.	2.9	74
112	The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCRâ€“ABL. Cancer Research, 2012, 72, 4890-4895.	0.4	73
113	Regulation of the Src protein tyrosine kinase. FEBS Letters, 1995, 369, 62-66.	1.3	69
114	BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood, 2010, 116, 3278-3285.	0.6	69
115	The deletion of the distal CCAAT box region of the Aî³-globin gene in Mack HPFH abolishes the binding of the erythroki specific protein NFE3 and of the CCAAT displacement protein. Nucleic Acids Research, 1989, 17, 6681-6691.	6.5	68
116	A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia, 2010, 24, 44-50.	3.3	67
117	Common Nodes of Virusâ€“Host Interaction Revealed Through an Integrated Network Analysis. Frontiers in Immunology, 2019, 10, 2186.	2.2	67
118	Initial characterization of the human central proteome. BMC Systems Biology, 2011, 5, 17.	3.0	66
119	Coincidental loss of DOCK8 function in NLRP10-deficient and C3H/HeJ mice results in defective dendritic cell migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3056-3061.	3.3	66
120	Virulence Factor NSs of Rift Valley Fever Virus Recruits the F-Box Protein FBXO3 To Degrade Subunit p62 of General Transcription Factor TFIIH. Journal of Virology, 2014, 88, 3464-3473.	1.5	65
121	The Bicarbonate Transporter SLC4A7 Plays a Key Role in Macrophage Phagosome Acidification. Cell Host and Microbe, 2018, 23, 766-774.e5.	5.1	65
122	Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis and Rheumatism, 2010, 62, 1608-1619.	6.7	64
123	KIT-D816Vâ€“independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood, 2011, 118, 1885-1898.	0.6	64
124	The -117 mutation in Greek HPFH affects the binding of three nuclear factors to the CCAAT region of the gamma-globin gene. EMBO Journal, 1988, 7, 3099-107.	3.5	64
125	Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl. Molecular Cell, 2005, 19, 461-473.	4.5	63
126	A Comparative Proteomic Study of Human Skin Suction Blister Fluid from Healthy Individuals Using Immunodepletion and iTRAQ Labeling. Journal of Proteome Research, 2012, 11, 3715-3727.	1.8	62

#	Article	IF	Citations
127	mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. Cell Reports, 2018, 23, 2157-2167.	2.9	62
128	Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nature Structural Biology, 1999, 6, 760-764.	9.7	61
129	Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis. Cell Chemical Biology, 2020, 27, 728-739.e9.	2.5	60
130	Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2. Journal of Clinical Investigation, 2016, 126, 4482-4496.	3.9	60
131	Caspase-Dependent Cleavage of c-Abl Contributes to Apoptosis. Molecular and Cellular Biology, 2003, 23, 2790-2799.	1.1	58
132	Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions. EMBO Journal, 1995, 14, 963-75.	3.5	58
133	After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorganic and Medicinal Chemistry, 2011, 19, 3616-3624.	1.4	54
134	Global survey of the immunomodulatory potential of common drugs. Nature Chemical Biology, 2017, 13, 681-690.	3.9	53
135	The RESOLUTE consortium: unlocking SLC transporters for drug discovery. Nature Reviews Drug Discovery, 2020, 19, 429-430.	21.5	53
136	The protein CDP, but not CP1, footprints on the CCAAT region of the Î³-globin gene in unfractionated B-cell extracts. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1989, 1007, 237-242.	2.4	52
137	Transcriptional Responses to IFN-Î³ Require Mediator Kinase-Dependent Pause Release and Mechanistically Distinct CDK8 and CDK19 Functions. Molecular Cell, 2019, 76, 485-499.e8.	4.5	52
138	Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity, 2015, 43, 974-986.	6.6	50
139	The Five Cleavage-Stage (CS) Histones of the Sea Urchin Are Encoded by a Maternally Expressed Family of Replacement Histone Genes: Functional Equivalence of the CS H1 and Frog H1M (B4) Proteins. Molecular and Cellular Biology, 1997, 17, 1189-1200.	1.1	49
140	The RNAâ€binding protein HuR/ELAVL1 regulates IFNâ€Î²ÂmRNA abundance and the type I IFN response. European Journal of Immunology, 2015, 45, 1500-1511.	1.6	49
141	Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 2016, 127, 362-365.	0.6	49
142	IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes. Experimental and Molecular Medicine, 2019, 51, 1-11.	3.2	49
143	Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia, 2016, 30, 464-472.	3.3	48
144	Developmental and tissue-specific regulation of a novel transcription factor of the sea urchin.. Genes and Development, 1989, 3, 663-675.	2.7	47

#	Article	IF	Citations
145	Nuclear tyrosine phosphorylation: the beginning of a map. Biochemical Pharmacology, 2000, 60, 1203-1215.	2.0	47
146	Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial Homeostasis. Developmental Cell, 2012, 23, 547-559.	3.1	47
147	Charting protein complexes, signaling pathways, and networks in the immune system. Immunological Reviews, 2006, 210, 187-207.	2.8	45
148	Functional crosstalk between membrane lipids and TLR biology. Current Opinion in Cell Biology, 2016, 39, 28-36.	2.6	44
149	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nature Chemical Biology, 2016, 12, 504-510.	3.9	43
150	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature Communications, 2018, 9, 1983.	5.8	43
151	Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia, 2008, 22, 2208-2216.	3.3	42
152	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology, 2013, 9, 705.	3.2	42
153	A time-resolved molecular map of the macrophage response to VSV infection. Npj Systems Biology and Applications, 2016, 2, 16027.	1.4	42
154	Polymerase Î´ deficiency causes syndromic immunodeficiency with replicative stress. Journal of Clinical Investigation, 2019, 129, 4194-4206.	3.9	41
155	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene, 2015, 34, 3780-3790.	2.6	40
156	A Surface Biotinylation Strategy for Reproducible Plasma Membrane Protein Purification and Tracking of Genetic and Drug-Induced Alterations. Journal of Proteome Research, 2016, 15, 647-658.	1.8	39
157	Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia, 2008, 22, 1184-1190.	3.3	38
158	Vienna special issue: Molecular machines. FEBS Letters, 2007, 581, 2749-2749.	1.3	37
159	An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B. Molecular Cancer Therapeutics, 2011, 10, 1846-1856.	1.9	37
160	Detection of Chemical Engagement of Solute Carrier Proteins by a Cellular Thermal Shift Assay. ACS Chemical Biology, 2018, 13, 1480-1486.	1.6	37
161	Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation. Nature Communications, 2021, 12, 7276.	5.8	37
162	The Purification and Characterization of the Catalytic Domain of Src Expressed in Schizosaccharomyces Pombe. Comparison of Unphosphorylated and Tyrosine Phosphorylated Species. FEBS Journal, 1996, 240, 756-764.	0.2	36

#	Article	IF	Citations
163	CytoplasmicListeria monocytogenesstimulates IFN-Î² synthesis without requiring the adapter protein MAVS. FEBS Letters, 2006, 580, 2341-2346.	1.3	36
164	A network solution. Nature, 2008, 455, 730-731.	13.7	36
165	Lapatinib potentiates cytotoxicity of ÂYM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter. Scientific Reports, 2017, 7, 3091.	1.6	35
166	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nature Chemical Biology, 2019, 15, 232-240.	3.9	34
167	Next generation of network medicine: interdisciplinary signaling approaches. Integrative Biology (United Kingdom), 2017, 9, 97-108.	0.6	32
168	The TLRâ€independent DNA recognition pathway in murine macrophages: Ligand features and molecular signature. European Journal of Immunology, 2009, 39, 1929-1936.	1.6	31
169	An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters. Frontiers in Pharmacology, 2021, 12, 722889.	1.6	31
170	A substrateâ€based ontology for human solute carriers. Molecular Systems Biology, 2020, 16, e9652.	3.2	31
171	A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases. Nature Biotechnology, 1996, 14, 600-605.	9.4	30
172	A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene, 2014, 33, 2531-2539.	2.6	29
173	The Src family of protein tyrosine kinases: regulation and functions. Development (Cambridge), 1993, 119, 57-64.	1.2	29
174	Selective serotonin reuptake inhibitorsâ€"A new modality for the treatment of lymphoma/leukaemia?. Biochemical Pharmacology, 2007, 74, 1424-1435.	2.0	28
175	Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk. Oncogene, 1995, 11, 2317-29.	2.6	28
176	Src regulated by C-terminal phosphorylation is monomeric. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3590-3595.	3.3	27
177	The chemokine interleukinâ€8 and the surface activation protein CD69 are markers for Bcrâ€"Abl activity in chronic myeloid leukemia. Molecular Oncology, 2008, 2, 272-281.	2.1	27
178	Systems biology analysis of proteinâ€drug interactions. Proteomics - Clinical Applications, 2012, 6, 102-116.	0.8	27
179	A method to resolve the composition of heterogeneous affinity-purified protein complexes assembled around a common protein by chemical cross-linking, gel electrophoresis and mass spectrometry. Nature Protocols, 2013, 8, 75-97.	5.5	27
180	Crystal structure of an SH2â€"kinase construct of c-Abl and effect of the SH2 domain on kinase activity. Biochemical Journal, 2015, 468, 283-291.	1.7	27

#	Article	IF	Citations
181	Protein interaction networks in innate immunity. Trends in Immunology, 2013, 34, 610-619.	2.9	26
182	The SH2 Domain Regulates c-Abl Kinase Activation by a Cyclin-Like Mechanism and Remodulation of the Hinge Motion. PLoS Computational Biology, 2014, 10, e1003863.	1.5	26
183	SLC38A9: A lysosomal amino acid transporter at the core of the amino acid-sensing machinery that controls MTORC1. Autophagy, 2016, 12, 1061-1062.	4.3	26
184	Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death and Differentiation, 2019, 26, 1138-1155.	5.0	26
185	A crystal milestone: The structure of regulated Src. BioEssays, 1997, 19, 447-450.	1.2	24
186	Phosphorylation of Brutonâ€™s tyrosine kinase by c-Abl. Biochemical and Biophysical Research Communications, 2002, 299, 510-515.	1.0	24
187	Regulation of c-Fes Tyrosine Kinase Activity by Coiled-Coil and SH2 Domains:â€‰ Analysis with Saccharomyces cerevisiae. Biochemistry, 2003, 42, 3567-3574.	1.2	24
188	Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRÎ±. Experimental Hematology, 2008, 36, 1244-1253.	0.2	24
189	Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17-mediated autoimmune arthritis. Arthritis Research and Therapy, 2015, 17, 230.	1.6	24
190	Insights into the transport side of the human SLC38A9 transceptor. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 1558-1567.	1.4	24
191	A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib. PLoS Computational Biology, 2010, 6, e1001001.	1.5	23
192	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	23
193	In silico Prioritization of Transporterâ€“Drug Relationships From Drug Sensitivity Screens. Frontiers in Pharmacology, 2018, 9, 1011.	1.6	23
194	Identifying Kinase Substrates via a Heavy ATP Kinase Assay and Quantitative Mass Spectrometry. Scientific Reports, 2016, 6, 28107.	1.6	22
195	Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Cell Death and Disease, 2016, 7, e2135-e2135.	2.7	22
196	Cross-species analysis of viral nucleic acid interacting proteins identifies TAOKs as innate immune regulators. Nature Communications, 2021, 12, 7009.	5.8	22
197	Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes. Journal of Proteome Research, 2013, 12, 4018-4027.	1.8	21
198	Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics. Molecular Cancer Therapeutics, 2014, 13, 2751-2762.	1.9	21

#	Article	IF	Citations
199	Targeting a cell state common to tripleâ€negative breast cancers. Molecular Systems Biology, 2015, 11, 789.	3.2	21
200	MASPECTRAS 2: An integration and analysis platform for proteomic data. Proteomics, 2010, 10, 2719-2722.	1.3	20
201	Crystal Structure of the Acid Sphingomyelinase-like Phosphodiesterase SMPDL3B Provides Insights into Determinants of Substrate Specificity. Journal of Biological Chemistry, 2016, 291, 24054-24064.	1.6	20
202	FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes. Laboratory Investigation, 2019, 99, 648-658.	1.7	20
203	The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. Virology, 2014, 462-463, 34-41.	1.1	18
204	Evaluating the Promiscuous Nature of Tyrosine Kinase Inhibitors Assessed in A431 Epidermoid Carcinoma Cells by Both Chemical- and Phosphoproteomics. ACS Chemical Biology, 2014, 9, 1490-1498.	1.6	18
205	eIF2B as a Target for Viral Evasion of PKR-Mediated Translation Inhibition. MBio, 2020, 11, .	1.8	18
206	Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe. Oncogene, 1996, 12, 1513-20.	2.6	18
207	Combinatorial Drug Screening Identifies Ewing Sarcomaâ€“specific Sensitivities. Molecular Cancer Therapeutics, 2017, 16, 88-101.	1.9	17
208	NSs Protein of Sandfly Fever Sicilian Phlebovirus Counteracts Interferon (IFN) Induction by Masking the DNA-Binding Domain of IFN Regulatory Factor 3. Journal of Virology, 2018, 92, .	1.5	17
209	Building and exploring an integrated human kinase network: Global organization and medical entry points. Journal of Proteomics, 2014, 107, 113-127.	1.2	16
210	Profiling of Small Molecules by Chemical Proteomics. Methods in Molecular Biology, 2016, 1394, 211-218.	0.4	16
211	A Miniaturized Chemical Proteomic Approach for Target Profiling of Clinical Kinase Inhibitors in Tumor Biopsies. Journal of Proteome Research, 2013, 12, 4005-4017.	1.8	15
212	A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. PLoS ONE, 2013, 8, e77155.	1.1	15
213	MMP13 mutations are the cause of recessive metaphyseal dysplasia, Spahr type. American Journal of Medical Genetics, Part A, 2014, 164, 1175-1179.	0.7	14
214	Structural Basis for Nucleotide Hydrolysis by the Acid Sphingomyelinase-like Phosphodiesterase SMPDL3A. Journal of Biological Chemistry, 2016, 291, 6376-6385.	1.6	13
215	The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection. Scientific Reports, 2019, 9, 10471.	1.6	13
216	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget, 2017, 8, 23061-23072.	0.8	13

#	Article	IF	Citations
217	Recent developments in ligands and chemical probes targeting solute carrier transporters. Current Opinion in Chemical Biology, 2021, 62, 53-63.	2.8	12
218	High-affinity Src-SH2 ligands which do not activate Tyr527-phosphorylated Src in an experimental in vivo system. Biochemical and Biophysical Research Communications, 2002, 298, 185-192.	1.0	11
219	Toward effective sharing of high-dimensional immunology data. Nature Biotechnology, 2014, 32, 755-759.	9.4	11
220	Genome-scale CRISPR screens are efficient in non-homologous end-joining deficient cells. Scientific Reports, 2019, 9, 15751.	1.6	11
221	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
222	The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia, 2019, 33, 2319-2323.	3.3	10
223	Patient-derived model systems and the development of next-generation anticancer therapeutics. Current Opinion in Chemical Biology, 2020, 56, 72-78.	2.8	10
224	Compound Immobilization and Drug-Affinity Chromatography. Methods in Molecular Biology, 2012, 803, 25-38.	0.4	10
225	Drugs in action. Nature Chemical Biology, 2008, 4, 7-11.	3.9	9
226	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	9
227	Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget, 2017, 8, 103014-103031.	0.8	9
228	Regulation of Human c-Abl Tyrosine Kinase Activity in <I>Xenopus</I> Oocytes and Acceleration of Progesterone-Induced G2/M Transition by Oncogenic Forms. Biological Chemistry, 1999, 380, 223-30.	1.2	8
229	Deconvolution of Targeted Proteinâ€“Protein Interaction Maps. Journal of Proteome Research, 2012, 11, 4102-4109.	1.8	8
230	Finally: The digital, democratic age of scientific abstracts. FEBS Letters, 2008, 582, 1169-1169.	1.3	7
231	Experimental characterization of the human non-sequence-specific nucleic acid interactome. Genome Biology, 2013, 14, R81.	13.9	7
232	Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states. Nature Metabolism, 2021, 3, 651-664.	5.1	7
233	Targeting allosteric regulatory modules in oncoproteins: â€œDrugging the Undruggableâ€• Oncotarget, 2011, 2, 828-829.	0.8	7
234	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nature Communications, 2021, 12, 7190.	5.8	7

#	Article	IF	Citations
235	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. Blood, 2007, 110, 1541-1541.	0.6	6
236	Interactome Networks. , 2013, , 45-63.		5
237	Identifying Core Protein Complexes from Downscaled Tandem Affinity Purifications. Journal of Integrated OMICS, 2012, 2, 55-68.	0.5	4
238	NMR Assignment Reveals an Î±-Helical Fold for the F-Actin Binding Domain of Human Bcr-Abl/c-Abl. Journal of Biomolecular NMR, 2005, 32, 335-335.	1.6	3
239	Systems Biology: Understanding the Biological Mosaic. FEBS Letters, 2005, 579, 1771-1771.	1.3	3
240	The testi-specific octamer-binding protein of the sea urchin has a molecular weight of 85 kDa. Nucleic Acids Research, 1989, 17, 7114-7114.	6.5	2
241	Analysis of TNFR2-mediated functions on osteoclast precursor cells. Annals of the Rheumatic Diseases, 2010, 69, A35-A36.	0.5	2
242	Cell biology: A key driver of therapeutic innovation. Journal of Cell Biology, 2012, 199, 571-575.	2.3	2
243	Enhancing cognate target elution efficiency in gel-free chemical proteomics. EuPA Open Proteomics, 2015, 9, 43-53.	2.5	2
244	Caught in the genetic network: a novel regulator of lipid metabolism. Nature Metabolism, 2020, 2, 483-484.	5.1	2
245	Impedance-Based Phenotypic Readout of Transporter Function: A Case for Glutamate Transporters. Frontiers in Pharmacology, 2022, 13, .	1.6	2
246	PTEN in antigen presenting cells is a master regulator for Th17-mediated autoimmune pathology. Arthritis Research and Therapy, 2012, 14, .	1.6	1
247	Special issue â€“ modular protein domains. FEBS Letters, 2012, 586, 2571-2571.	1.3	1
248	A1.8â€...A dual role of MTOR in the rheumatoid mesenchymal tissue response to inflammation. Annals of the Rheumatic Diseases, 2014, 73, A3.3-A4.	0.5	1
249	Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.. Blood, 2007, 110, 4542-4542.	0.6	1
250	Targeting solute carriers to modulate receptorâ€“ligand interactions. Trends in Pharmacological Sciences, 2022, , .	4.0	1
251	Spotlight onâ€¦ Giulio Superti-Furga. FEBS Letters, 2005, 579, 2253-2253.	1.3	0
252	Mechanisms of Activation of Abl Family Kinases. , 2006, , 1-10.		0

#	Article	IF	Citations
253	311 Molecular networks in innate immunity. Cytokine, 2008, 43, 317.	1.4	0
254	A biomedical adventurers' guide to navigating between careers in academia and industry. Nature Reviews Molecular Cell Biology, 2009, 10, 884-887.	16.1	0
255	Mass Spectrometry and its Applications to Functional Proteomics. , 2010, , 307-323.		0
256	P120 The cytokine mRNA-interactome â€“ An unbiased approach to identify RNAâ€“protein interactions. Cytokine, 2012, 59, 558.	1.4	0
257	Functional Dissection of Dynamic Molecular Networks in Innate Immunity. Biophysical Journal, 2012, 102, 9a.	0.2	0
258	Target/s Identification Approaches â€“ Experimental Biological Approaches. RSC Drug Discovery Series, 2012, , 94-110.	0.2	0
259	Recruitment of the MLL complex via specific interaction of the p30 variant of C/EBPÎ± with Wdr5 is essential for development of acute myeloid leukemia. Experimental Hematology, 2013, 41, S20.	0.2	0
260	Elucidating the molecular mechanism of action of cancer drugs in the second decade of the new millennium. Experimental Hematology, 2013, 41, S9.	0.2	0
261	A6.14â€¦mTOR Directed Mesenchymal Tissue Response to Inflammation in Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A47.1-A47.	0.5	0
262	Comparative functional analysis of the molecular network of 7 selected MLL fusion proteins. Experimental Hematology, 2014, 42, S60.	0.2	0
263	Systems biology. , 2015, , 134-138.		0
264	A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.. Blood, 2006, 108, 2188-2188.	0.6	0
265	Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia.. Blood, 2007, 110, 2936-2936.	0.6	0
266	Functional Genomic and Proteomic Characterization of Normal and Oncogenic CEBPA Variants In Myeloid Cells. Blood, 2010, 116, 3873-3873.	0.6	0
267	Bcr-Abl Directly Activates Stat5 Independent of Jak2. Blood, 2010, 116, 511-511.	0.6	0
268	Systems Biology Analysis of Kinase Inhibitor Protein Target Profiles in Leukemia Treatments. Lecture Notes in Computer Science, 2012, , 62-66.	1.0	0
269	Abstract 5038: Probing network fragilities in neuroblastoma by synergistic drug combinations.. , 2013, , .		0